NCT lookup

Inclusion Criteria:

* MS according to 2010 revised McDonald criteria (76);
* Expanded disability status scale (EDSS) of 0-6.5 inclusive;
* Disease duration of maximum 15 years and first signs or symptoms at least 6 months prior to enrolment in the study;
* Active MS (relapsing and progressive): -1 relapse in the past year and/or

  * at least 1 enhancing lesion on brain MRI in the past year
  * new or enlarging T2 lesion(s) in comparison with a reference scan from maximum 1 year before
* Neurologically stable with no evidence of relapse for at least 30 days prior to start of screening and throughout during the screening phase;
* Positive T cell reactivity response to a mix of 7 myelin-derived peptides;
* Able to sign informed consent;
* Ability to comply with the protocol assessments;
* Appropriate venous access.
* Use of adequate contraceptive measures

Exclusion Criteria:

* Previous use of immunosuppressive or cytostatic treatment, including mitoxantrone, alemtuzumab or bone marrow transplantation or stem cell transplantation at any time prior to enrolment;
* Treatment with fingolimod or natalizumab or dimethylfumarate or teriflunomide within the last 3 months prior to study enrolment;
* Pregnancy or planning pregnancy in the next 12 months and breast feeding;
* Drug or alcohol abuse;
* Inability to undergo MRI assessments;
* History of or actual signs of immunodeficiency or malignancies;
* Concurrent clinically relevant cardiac, immunological, pulmonary, neurological, renal or other major disease;
* Hepatitis B, C, HIV, Syphilis or tuberculosis
* Splenectomy;
* Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity that could interfere with the compliance to the protocol.

• Edegem, Belgium